Skip to content
Menu

Gossamer Bio, Inc. GOSS

Full chart Compare
Set alert

Price alert · GOSS

All alert types
10.72 USD -0.51 (-4.54%)

Regular-session close

10.72 0.00 0.00%

After hours · Nov 20, 4:00 PM ET

10.65 Day range 11.60
8.43 52-week range 303.20
YTD
-95.68%
1 year
-95.69%

5D +0.25 (+2.31%)

10.501111.50FriMonTueWedThu11.05
Market cap
65.57M
Revenue (ttm)
53.29M
Profit margin
-235.00%
EPS (ttm)
-42.41
Shares out
488.85M
Forward P/E
-0.69
YTD return
-95.68%
1-year return
-95.69%
Volume
191.43K
Avg volume
266.06K
Open
11.02
Previous close
11.23
Day's range
10.65 – 11.60
52-week range
8.43 – 303.20
Beta
2.00
Price target
132.48 (+1135.8%)

Key statistics

50-day average
13.50
200-day average
78.36
Enterprise value
52.65M
Price / sales
98.44
Revenue growth
-19.60%
Free cash flow
-29.76M
Total cash
57.03M
Total debt
40.07M
Short % of float
0.21%

Fundamental scorecard

3 of 25 checks passed on GOSS’s reported financials

ValueGrowthProfitabilityHealthDividend

3of 25 checks passed

  • Value 0 of 5
  • Growth 2 of 5
  • Profitability 0 of 5
  • Financial health 1 of 5
  • Dividend 0 of 5

Statements to Sep 30, 2026.

Financials — quick view

All financials
GOSS Revenue — quarterly 38.43M
GOSS Net income — quarterly -48.07M
GOSS EPS — quarterly -7.36

Earnings

GOSS recent earnings
Report dateQuarter endingEPS estimateEPS reportedSurpriseSurprise %
Nov 4, 2026Sep 30, 2026-3.69———
Aug 13, 2026Jun 30, 2026-9.87-0.20+9.67+97.97%
May 18, 2026Mar 31, 2026-13.60-0.20+13.40+98.53%
Mar 18, 2026Dec 31, 2025-16.00-0.21+15.79+98.69%
Nov 6, 2025Sep 30, 2025-15.20-16.80-1.60-10.53%
Aug 11, 2025Jun 30, 2025-14.40-0.17+14.23+98.82%

Upgrades / downgrades

GOSS analyst upgrades and downgrades
DateFirmActionFromTo
Aug 14, 2026Piper SandlermainOverweightOverweight
Jul 28, 2026Leerink PartnersupMarket PerformOutperform
Jul 27, 2026HC Wainwright & Co.reitBuyBuy
Jun 25, 2026HC Wainwright & Co.mainBuyBuy
May 26, 2026HC Wainwright & Co.reitBuyBuy
May 19, 2026BarclaysmainUnderweightUnderweight

About Gossamer Bio, Inc.

Gossamer Bio, Inc., a clinical-stage biopharmaceutical company, focuses on developing and commercializing seralutinib for the treatment of pulmonary hypertension and pulmonary arterial hypertension in the United States. The company develops GB002, an inhaled, small molecule, platelet-derived growth factor receptor, or PDGFR, colony-stimulatin factor 1 receptor and c-KIT inhibitor, which is in Phase 3 clinical trial for the treatment of PAH. It has license agreements with Pulmokine, Inc. to develop and commercialize GB002 and related backup compounds. The company was formerly known as FSG, Bio, Inc. and changed its name to Gossamer Bio, Inc. in 2017. The company was incorporated in 2015 and is headquartered in San Diego, California.

Sector
Healthcare
Industry
Biotechnology
Country
United States

News

Your note

Sign in to keep a note on GOSS — it syncs with the Stock Master app.

Insider holders

GOSS insider holders
InsiderRelationLatest transactionDateShares held
ARANDA RICHARDOfficerStock Award(Grant)Jan 1, 2026465,645
CHRISTIAN WAAGEOfficerStock Award(Grant)Jan 1, 2026882,175
GIRAUDO BRYAN M.Chief Operating OfficerStock Award(Grant)Jan 1, 2026869,747
HASNAIN FAHEEMChief Executive OfficerStock Award(Grant)Jan 1, 20266,245,870
MILLIGAN SANDRADirectorPurchaseAug 18, 202558,050
PETERSON CARYNOfficerStock Award(Grant)Jan 1, 2026259,333

Institution ownership

GOSS institution ownership
Holder% heldSharesValueReported
Shaw D.E. & Co., Inc.8.38%40,959,285439.49MJun 29, 2026
683 Capital Management LLC8.02%39,198,868420.60MJun 29, 2026
DeepCurrents Investment Group, LLC7.70%37,665,073404.15MJun 29, 2026
Context Capital Management, LLC5.92%28,946,459310.60MJun 29, 2026
Worth Venture Partners, Llc5.12%25,017,881268.44MJun 29, 2026
AQR Capital Management, LLC3.20%15,629,993167.71MJun 29, 2026

Fund ownership

GOSS fund ownership
Holder% heldSharesValueReported
VANGUARD INDEX FUNDS-Vanguard Total Stock Market Index Fund1.41%6,910,93474.15MJun 29, 2026
VANGUARD INDEX FUNDS-Vanguard Extended Market Index Fund0.46%2,243,30524.07MJun 29, 2026
iShares Trust-iShares Biotechnology ETF0.31%1,501,11616.11MJun 29, 2026
SCHWAB STRATEGIC TRUST-Schwab U.S. Small-Cap ETF0.20%986,82610.59MMay 30, 2026
VANGUARD SCOTTSDALE FUNDS-Vanguard Russell 2000 Index Fund0.20%977,03010.48MMay 30, 2026
VANGUARD WORLD FUND-Vanguard Health Care Index Fund0.11%541,9505.82MMay 30, 2026